This ExpertREACT article was originally published on 9 June 2008 following Novartis Vaccines' R&D Day. Pipeline data and competitive positions described reflect the state of knowledge at that date.
Novartis Vaccines in 2008: $1.5bn and growing
Novartis entered the global vaccines market in 2005 through its takeover of California-based Chiron, and had since strengthened its presence in influenza (Fluad/Fluvirin) and travel vaccine segments (Encepur for TBE, Ixiaro for JE). The company generated sales of $1.5bn in 2007 - approximately 10% of the top five major players' combined sales - but unlike its main rivals conspicuously lacked a significant presence in the core paediatric market. Novartis' R&D Day presentation focused on addressing this weakness through accelerated development of Menveo (MenACWY-CRM conjugate) and the MenB vaccine - both predicted to become blockbusters targeting the most important remaining vaccine-preventable serogroup.
For Menveo, Novartis had presented data showing strong protective immune response in individuals from two months to 17 years of age. The most commercially significant feature was coverage of infants under two years - an age group critical for schedule inclusion. For MenB, new data for the investigational recombinant meningococcal Group B vaccine (4CMenB, later Bexsero) demonstrated encouraging immunogenicity. With a significant head start on Pfizer's rLP2086 MenB programme, VacZine Analytics projected that Novartis would file for the first broad-coverage MenB vaccine in approximately 2010 - subject to Phase III completion.
A rich early-stage pipeline: forcing rivals to act
Beyond the headline MenB and Menveo programmes, Novartis revealed a rich early-stage pipeline at the R&D Day that included several genuinely first-in-class candidates. Nosocomial infection vaccines - targeting Clostridium difficile (Phase II), Pseudomonas aeruginosa and Staphylococcus aureus - represented a new commercial frontier that Novartis was pioneering. Early-stage programmes for RSV, Helicobacter pylori, Group A Streptococcus (GAS) and Group B Streptococcus (GBS) were also disclosed. VacZine Analytics viewed this pipeline diversity as a serious strategic signal - not only were Novartis' near-term products compelling, but the breadth of their early-stage programmes would force rivals to invest more aggressively in novel vaccine categories or cede competitive ground in the medium to long term.